On November 4, 2021 MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, reported that three abstracts highlighting data and information from three oncology drug candidates in its pipeline will be presented at the upcoming 63rd Annual American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting to be held December 11 – 14, 2021 (Press release, MEI Pharma, NOV 4, 2021, View Source [SID1234594529]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on the poster presentations are included below:

Title: Coastal: A Phase 3 Study of the PI3Kδ Inhibitor Zandelisib with Rituximab (R) Versus Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin’s Lymphoma (iNHL)
Authors: Wojciech Jurczak, M.D., Ph.D., et. al.
Date: Sunday, December 12, 2021, 6:00 PM – 8:00 PM ET
Abstract ID: 2430

Summary of study methods: the COASTAL study is a randomized, open-label, controlled multicenter phase 3 trial to investigate the safety and efficacy of zandelisib in combination with rituximab versus standard immunochemotherapy in patients with relapsed or refractory follicular or marginal zone lymphomas who received at least one prior line of therapy. Eligible patients must have received an anti-CD20 antibody in combination with chemotherapy or lenalidomide.

Title: A Novel Isoflavone, ME-344, Enhances Venetoclax Antileukemic Activity Against AML Via Suppression of Oxidative Phosphorylation and Purine Biosynthesis
Authors: Katie Hurrish, et. al.
Date: Sunday, December 12, 2021, 6:00 PM – 8:00 PM ET
Abstract ID: 2238

Summary of results: preclinical studies evaluating the combination of ME-344 with venetoclax in AML cell lines, including those with cytarabine resistance, and in an AML patient sample, suggest that ME-344 suppresses OXPHOS and the purine biosynthesis pathway to enhance the antileukemic activity of venetoclax against AML.

Title: A Phase 1 Dose-Escalation Study of the Oral CDK Inhibitor Voruciclib in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia (AML): Preliminary Results of the Completed Dose Escalation Stage in AML
Authors: Marina Konopleva, M.D., Ph.D., et. al.
Date: Monday, December 13, 2021, 6:00 PM – 8:00 PM ET
Abstract ID: 3423

Summary of conclusions: voruciclib administered on an optimized schedule of 14 consecutive days in a 28-day cycle was well tolerated. Further, no dose limiting toxicities were observed and no significant myelosuppression was seen in patients with B-cell malignancies, suggesting no overlapping toxicities with venetoclax. Disease stabilization was observed in heavily pretreated patients and differentiation syndrome was observed in AML patients indicating biologic activity. A protocol amendment is forthcoming to evaluate voruciclib in combination with venetoclax in patients with relapsed AML.

The abstracts are available on the ASH (Free ASH Whitepaper) annual meeting website. The e-poster presentations will be available on the MEI Pharma website on the morning each poster opens for viewing at ASH (Free ASH Whitepaper).